TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Moleculin Biotech ( (MBRX) ) has issued an announcement.
On November 13, 2025, Moleculin Biotech announced that 60% of the target subjects have consented to participate in its pivotal Phase 2B/3 MIRACLE study of Annamycin for treating relapsed or refractory acute myeloid leukemia (AML). The company aims to complete treatment of the first 45 subjects by the first quarter of 2026, with initial unblinding of data expected thereafter. Despite some recruitment challenges in Europe, the study is progressing well, and Moleculin is optimistic about Annamycin’s potential to address a significant gap in AML treatment.
The most recent analyst rating on (MBRX) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Moleculin Biotech stock, see the MBRX Stock Forecast page.
Spark’s Take on MBRX Stock
According to Spark, TipRanks’ AI Analyst, MBRX is a Neutral.
Moleculin Biotech’s stock score reflects a high-risk financial position with no revenue and growing losses typical of early-stage biotech firms. Positive developments in clinical trials and a solid financial runway provide potential upside, but significant risks remain due to financial instability, high trial costs, and future funding needs. Technical indicators suggest bearish momentum, and the valuation is unattractive due to the absence of earnings.
To see Spark’s full report on MBRX stock, click here.
More about Moleculin Biotech
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company focused on developing therapeutic candidates for hard-to-treat tumors and viruses. Its lead program, Annamycin, is designed to treat relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases, with a focus on avoiding multidrug resistance and cardiotoxicity.
Average Trading Volume: 4,041,858
Technical Sentiment Signal: Sell
Current Market Cap: $24.14M
For detailed information about MBRX stock, go to TipRanks’ Stock Analysis page.